If favourable, we expect an additional global Phase III study will be required before emergency use authorisation. We value BGBIO at NOK4.72bn.
BerGenBio (BGBIO) has announced preliminary data for lead asset bemcentinib, an oral once daily highly selective AXL inhibitor for the treatment of severe COVID-19 infections requiring hospitalisation. In the Phase II ACCORD-2 and BGBC020 trials, treatment with bemcentinib led to numerically fewer deaths versus standard of care up to day 29.
LÄS MER